Literature DB >> 24128829

Association of tumor size with metastatic potential and survival in patients with adrenocortical carcinoma: an analysis of the National Cancer Database.

Daniel J Canter1, Katherine Mallin, Robert G Uzzo, Brian L Egleston, Jay Simhan, John Walton, Marc C Smaldone, Viraj A Master, Gennady Bratslavsky, Alexander Kutikov.   

Abstract

INTRODUCTION: To assess the impact of size at presentation in patients with adrenocortical carcinoma (ACC) on rates of synchronous metastatic disease and survival following resection using a large administrative dataset.
MATERIALS AND METHODS: We queried the National Cancer Database (NCDB) dataset to assemble a cohort of patients with ACC based on SEER staging (1985-2000). Patients were stratified into three groups based on surgical tumor size cutoffs: < 4 cm, 4 cm-6 cm, and > 6 cm. Rates of metastatic disease at presentation in all ACC patients as well as relative survival for patients after resection of localized lesions were calculated and compared among groups.
RESULTS: A total of 2248 patients had available staging information for analysis. Tumor size at presentation did not relate to likelihood of non-localized disease at presentation (p = 0.09). A restricted cubic splines analysis revealed a clinically insignificant relationship between tumor size and advanced disease at presentation (OR = 1.02 for each centimeter change in tumor size, p = 0.004, 95% CI 1.01-1.03). On multivariate analysis, only patient age (p < 0.01), and not tumor size, was a significant predictor of overall survival among patients undergoing resection of localized ACCs.
CONCLUSIONS: Our data suggest that tumor size is imperfect in predicting presence of distant disease at presentation, nor does it consistently correlate with patient survival after resection of localized ACC.

Entities:  

Mesh:

Year:  2013        PMID: 24128829

Source DB:  PubMed          Journal:  Can J Urol        ISSN: 1195-9479            Impact factor:   1.344


  8 in total

1.  Actual 10-year survivors following resection of adrenocortical carcinoma.

Authors:  Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Jason D Prescott; Tracy S Wang; Jason Glenn; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; Ioannis Hatzaras; Rivfka Shenoy; Timothy M Pawlik; Jeffrey A Norton; George A Poultsides
Journal:  J Surg Oncol       Date:  2016-09-16       Impact factor: 3.454

2.  Curative Surgical Resection of Adrenocortical Carcinoma: Determining Long-term Outcome Based on Conditional Disease-free Probability.

Authors:  Yuhree Kim; Georgios A Margonis; Jason D Prescott; Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Tracy S Wang; Jason A Glenn; Ioannis Hatzaras; Rivfka Shenoy; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; George A Poultsides; Timothy M Pawlik
Journal:  Ann Surg       Date:  2017-01       Impact factor: 12.969

3.  Neutrophil-lymphocyte and platelet-lymphocyte ratio as predictors of disease specific survival after resection of adrenocortical carcinoma.

Authors:  Fabio Bagante; Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Tracy S Wang; Douglas B Evans; Ioannis Hatzaras; Rivfka Shenoy; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; George A Poultsides; Timothy M Pawlik
Journal:  J Surg Oncol       Date:  2015-07-31       Impact factor: 3.454

4.  Nomograms to Predict Recurrence-Free and Overall Survival After Curative Resection of Adrenocortical Carcinoma.

Authors:  Yuhree Kim; Georgios A Margonis; Jason D Prescott; Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Tracy S Wang; Douglas B Evans; Ioannis Hatzaras; Rivfka Shenoy; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed I Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; George A Poultsides; Timothy M Pawlik
Journal:  JAMA Surg       Date:  2016-04       Impact factor: 14.766

5.  A nomogram for individualized estimation of survival among adult patients with adrenocortical carcinoma after surgery: a retrospective analysis and multicenter validation study.

Authors:  Jianqiu Kong; Junjiong Zheng; Jinhua Cai; Shaoxu Wu; Xiayao Diao; Weibin Xie; Xiong Chen; Chenyi Liao; Hao Yu; Xinxiang Fan; Chaowen Huang; Zhuowei Liu; Wei Chen; Qiang Lv; Haide Qin; Jian Huang; Tianxin Lin
Journal:  Cancer Commun (Lond)       Date:  2019-11-27

6.  The prognosis of different distant metastases pattern in malignant tumors of the adrenal glands: A population-based retrospective study.

Authors:  Jia Miao; Haibin Wei; Jianxin Cui; Qi Zhang; Feng Liu; Zujie Mao; Dahong Zhang
Journal:  PLoS One       Date:  2022-03-15       Impact factor: 3.240

Review 7.  Open versus minimally invasive surgery for suspected adrenocortical carcinoma.

Authors:  Dylan M Buller; Alex M Hennessey; Benjamin T Ristau
Journal:  Transl Androl Urol       Date:  2021-05

8.  Biology is Destiny: A Case of Adrenocortical Carcinoma Diagnosed and Resected at Inception in a Patient Under Close Surveillance for Lung Cancer.

Authors:  Benjamin Miron; Benjamin T Ristau; Jeffrey J Tomaszewski; Josh Jones; Bart Milestone; Yu-Ning Wong; Robert G Uzzo; Donna Edmondson; Walter Scott; Alexander Kutikov
Journal:  Urol Case Rep       Date:  2016-08-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.